PT  - JOURNAL ARTICLE
AU  - Scott, Karen
AU  - Chappell, Elizabeth
AU  - Mostafa, Aya
AU  - Volokha, Alla
AU  - Najmi, Nida
AU  - Ebeid, Fatma
AU  - Posokhova, Svitlana
AU  - Sikandar, Raheel
AU  - Vasylyev, Marta
AU  - Zulfiqar, Saima
AU  - Kaminskyi, Viacheslav
AU  - Pett, Sarah
AU  - Malyuta, Ruslan
AU  - Hamid, Saeed
AU  - El-Sayed, Manal H
AU  - Gibb, Diana
AU  - Judd, Ali
AU  - Collins, Intira Jeannie
TI  - Acceptability of HCV screening and potential use of DAAs during pregnancy in women attending antenatal care in Egypt, Pakistan and Ukraine
AID  - 10.1101/2021.09.29.21264171
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.09.29.21264171
4099  - http://medrxiv.org/content/early/2021/10/08/2021.09.29.21264171.short
4100  - http://medrxiv.org/content/early/2021/10/08/2021.09.29.21264171.full
AB  - Background The risk of vertical transmission of hepatitis C virus (HCV) is ≈6%, and evidence suggests HCV negatively affects pregnancy and infant outcomes. Despite this, universal antenatal HCV screening is not available in most settings, and direct acting antivirals (DAA) are yet to be approved for use in pregnancy or breastfeeding period. Larger safety and efficacy trials are needed. At current there is limited understanding of the acceptability of routine HCV screening and use of DAAs in pregnancy but only among women in high HCV burden countries.Methods We conducted a cross-sectional survey of pregnant or post-partum (<6 months since delivery) women attending antenatal clinics or maternity hospitals in Egypt, Pakistan and Ukraine. In Ukraine, this included one HIV clinic. Acceptability of free universal antenatal HCV screening and potential uptake of DAA treatment in the scenario of DAAs being approved for use in pregnancy was assessed. Results were stratified by HCV status and in Ukraine by HIV status. Descriptive statistics were used to explore differences in acceptability of treatment in pregnancy by country.Findings Among 630 women (n=210 per country) who participated, the median age was 30 [interquartile range (IQR) 26, 34] years, 73% were pregnant and 27% postpartum, and 27% ever HCV antibody or PCR positive. 40% of women in Ukraine were living with HIV. Overall 93% of women supported free universal HCV screening in pregnancy, with no difference by country. 88% would take DAAs in pregnancy if approved for use: 92%, 98% and 73% among women in Egypt, Pakistan and Ukraine, respectively. Motivation for use of DAAs in pregnancy (to avert vertical transmission or for maternal HCV cure) varied by country, HCV status and HIV status (in Ukraine). No predictors for acceptability of DAAs were identified.Interpretation Our survey across 3 high burden countries found very high acceptability of free universal HCV screening and DAAs if approved for use in pregnancy. Clinical trials to evaluate the safety and efficacy of DAAs during pregnancy and breastfeeding are urgently required.Funding This survey was conducted as part of the “HCVAVERT” study, funded by the UK Medical Research Council (ref MR/R019746/1).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis survey was conducted as part of the HCVAVERT study, funded by the UK Medical Research Council (ref MR/R019746/1).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UCL Research Ethics CommitteeI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData sharing requests may be made in writing to UCL